Add 2 More Reports For 20% off

Report Overview

Several studies suggest that 35 to 45% of patients having cirrhosis experience overt hepatic encephalopathy. The cumulative incidence of hepatic encephalopathy in cirrhosis is 5% to 20% at five years and 7% to 40% at 10 years. Treatment of hepatic encephalopathy includes several ammonia-lowering therapies like non-absorbable disaccharides and antimicrobial agents such as rifaximin and l-ornithine l-aspartat. Approximately 25 clinical studies are ongoing to develop innovative treatments for overt hepatic encephalopathy, including antimicrobials, and osmotic laxative among others.

  • Major companies involved in the overt hepatic encephalopathy pipeline drugs market include Pfizer and Amgen among others.
  • Leading drugs currently under pipeline include Bausch Health Americas, Inc. and Axcella Health, Inc. among others.
  • Regulatory authorities such as the United States FDA and EMA play an essential role in overt hepatic encephalopathy treatment as they are offering breakthrough designations to manage the condition.

Report Coverage

The Overt Hepatic Encephalopathy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into overt hepatic encephalopathy clinical trials. It covers various aspects related to the details of each of these drugs under development for overt hepatic encephalopathy. The report includes the analysis of over 20+ pipeline drugs and 10+ companies. The overt hepatic encephalopathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from overt hepatic encephalopathy. 

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing overt hepatic encephalopathy product development activities.

Overt Hepatic Encephalopathy Drug Pipeline Outlook

Overt hepatic encephalopathy is a reversible neurological complication of cirrhosis which is caused by liver dysfunction. This disease affects the central nervous system and affects how a person thinks, feels, and acts. The symptom of overt hepatic encephalopathy varies and ranges from disorientation to erratic behavior and personality changes.  

The disorder is caused by neurotoxins (substances which are toxic to the brain and nervous system) in the blood. When the liver doesn’t filter these toxins from the blood, these neurotoxins continue to circulate, eventually entering and affecting the brain. It usually occurs in advanced liver disease when the function of the liver begins to fail. The disorder can affect personality, mood, consciousness, sleep patterns, concentration and thinking, behavior along with impulse control among others. 

There are three types of hepatic encephalopathy including type A, type B and type C. Type A is caused by acute liver failure. It is a sudden loss of liver function due to severe liver injury. Type B is caused by a portosystemic shunt when blood flow bypasses its normal route through a new and abnormal passageway and type C is caused by chronic liver failure. The medications given to treat the conditions include rifaximin, and lactulose among others. Rifaximin antibiotic is nonabsorbable by intestines and actulose is a synthetic laxative that draws water into the bowel. The supplemental medications given are amino acids to build muscle and clear ammonia from blood and probiotics to encourage healthy gut bacteria to compete with the less helpful types of bacteria which produce neurotoxins. Several pharma companies and research institutes are developing innovative treatments to manage overt hepatic encephalopathy. According to the National Institute of Health, several clinical trial studies suggest that rifaximin has shown significant beneficial effect on the improvement of overt hepatic encephalopathy. The increasing clinical trials and changing dynamics are impacting the overt hepatic encephalopathy clinical trial landscape significantly.

Overt Hepatic Encephalopathy – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of overt hepatic encephalopathy drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase:

  • Late-Stage Products (Phase 3 and Phase 4)  
  • Mid-Stage Products (Phase 2)  
  • Early-Stage Products (Phase I)  
  • Preclinical and Discovery Stage Products

By Drug Class

EMR’s overt encephalopathy assessment report covers 100+ drug analyses based on drug classes:

  • Peptides 
  • Recombinant Proteins 
  • Small Molecule 

By Route of Administration

EMR’s pipeline assessment report covers 100+ drug analyses based on the route of administration:

  • Oral
  • Parenteral
  • Others

Overt Hepatic Encephalopathy – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total clinical trials for overt hepatic encephalopathy.

Overt Hepatic Encephalopathy – Pipeline Assessment Segmentation, By Drug Class

The drug molecules categories covered under overt hepatic encephalopathy pipeline analysis include peptides, recombinant proteins, and small molecules. L-ornithine and L-aspartate are endogenous amino acids which help with ammonia detoxification. Several trials are suggesting the potential beneficial role of L-ornithine and L-aspartate for the treatment of overt hepatic encephalopathy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for overt hepatic encephalopathy.

Overt Hepatic Encephalopathy Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the overt hepatic encephalopathy drug insights covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed overt hepatic encephalopathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Overt Hepatic Encephalopathy clinical trials: 

  • Bausch Health Americas, Inc. 
  • Axcella Health, Inc. 
  • Ocera Therapeutics, Inc. 
  • Mallinckrodt 
  • Others

Overt Hepatic Encephalopathy – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for overt hepatic encephalopathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of overt hepatic encephalopathy drug candidates.

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for overt hepatic encephalopathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of overt hepatic encephalopathy drug candidates.

Drug: 40 mg Rifaximin SSD

The trial is designed to evaluate the safety of Rifaximin Soluble Solid Dispersion tablets and Lactulose for overt hepatic encephalopathy treatment. The trial is sponsored by Bausch Health Americas and is currently under phase II.

Drug: AXA1665

The objective of the study is to compare and assess the safety and tolerability of AXA1665. It is an...

Drug: Ornithine Phenylacetate

Ocera Therapeutics, Inc. is developing the drug and is currently under phase II. The study is being ...

*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*

Reasons To Buy This Report

The Overt Hepatic Encephalopathy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for overt hepatic encephalopathy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into rovert hepatic encephalopathy collaborations, regulatory environments, and potential growth opportunities within overt hepatic encephalopathy pipeline insights.

Key Questions Answered in the Overt Hepatic Encephalopathy – Pipeline Insight Report

  • Which companies/institutions are leading the overt hepatic encephalopathy drug development? 
  • What is the efficacy and safety profile of overt hepatic encephalopathy pipeline drugs? 
  • Which company is leading the overt hepatic encephalopathy pipeline development activities? 
  • What is the current overt hepatic encephalopathy commercial assessment? 
  • What are the opportunities and challenges present in the overt hepatic encephalopathy drug pipeline landscape? 
  • What is the efficacy and safety profile of overt hepatic encephalopathy pipeline drugs? 
  • Which company is conducting major trials for overt hepatic encephalopathy drugs? 
  • Which companies/institutions are involved in overt hepatic encephalopathy collaborations aimed at providing enhanced therapeutic alternatives for patients? 
  • What are the geographies covered for clinical trials in overt hepatic encephalopathy?

Related Reports

Hepatic Encephalopathy Treatment Market

Global Hepatic Disease Treatment Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Drug Pipeline by Clinical Trial Phase

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

Route of Administration

  • Oral
  • Parenteral
  • Others

Drug Classes

  • Peptides
  • Recombinant Proteins
  • Small Molecule

Leading Sponsors Covered

  • Bausch Health Americas, Inc.
  • Axcella Health, Inc.
  • Ocera Therapeutics, Inc.
  • Mallinckrodt
  • Others

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Selected Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Selected Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124